Creating new antimalarial drugs using advanced chemical methods
High throughput chemoenzymatic synthesis of antimalarial compounds
['FUNDING_R21'] · UNIVERSITY OF MICHIGAN AT ANN ARBOR · NIH-10691400
This study is working on creating new medicines to help fight malaria, a disease that affects many people, by using natural plant ingredients to find better treatments that can work even when the parasites become resistant to current drugs.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MICHIGAN AT ANN ARBOR (nih funded) |
| Locations | 1 site (ANN ARBOR, UNITED STATES) |
| Trial ID | NIH-10691400 on ClinicalTrials.gov |
What this research studies
This research focuses on developing new antimalarial compounds to combat malaria, a disease that affects millions worldwide. The approach involves high throughput chemoenzymatic synthesis, which allows for the rapid creation of potential new drugs. By exploring natural plant metabolites and their derivatives, the research aims to identify effective treatments that can overcome the growing issue of drug resistance in malaria-causing parasites. Patients may benefit from innovative therapies that could provide more effective treatment options against malaria.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk of malaria infection, particularly those living in endemic regions.
Not a fit: Patients who are not at risk of malaria or those who have already been treated with existing antimalarial drugs may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new, effective antimalarial drugs that can save lives and reduce the burden of malaria.
How similar studies have performed: Other research has successfully developed new antimalarial compounds using similar approaches, indicating a promising avenue for future breakthroughs.
Where this research is happening
ANN ARBOR, UNITED STATES
- UNIVERSITY OF MICHIGAN AT ANN ARBOR — ANN ARBOR, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: NARAYAN, ALISON — UNIVERSITY OF MICHIGAN AT ANN ARBOR
- Study coordinator: NARAYAN, ALISON
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.